These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
385 related items for PubMed ID: 25569737
1. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Zitomersky NL, Atkinson BJ, Fournier K, Mitchell PD, Stern JB, Butler MC, Ashworth L, Hauenstein S, Heiner L, Chuang E, Singh S, Bousvaros A. Inflamm Bowel Dis; 2015 Feb; 21(2):307-14. PubMed ID: 25569737 [Abstract] [Full Text] [Related]
2. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Eliakim R, Ben-Horin S, ABIRISK consortium. Gut; 2014 Aug; 63(8):1258-64. PubMed ID: 24041539 [Abstract] [Full Text] [Related]
3. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S. J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875 [Abstract] [Full Text] [Related]
4. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Hofmekler T, Bertha M, McCracken C, Martineau B, McKinnon E, Schoen BT, McElhanon BO, Tenjarla G, Kugathasan S, Sauer CG. J Pediatr Gastroenterol Nutr; 2017 Apr; 64(4):580-585. PubMed ID: 28079601 [Abstract] [Full Text] [Related]
12. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Bar-Yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, Fudim E, Kopylov U, Eliakim R, Ben-Horin S, Chowers Y, Ungar B. Aliment Pharmacol Ther; 2018 Jan; 47(2):212-218. PubMed ID: 29124774 [Abstract] [Full Text] [Related]